" class="no-js "lang="en-US"> James G. Evans - Medtech Alert
Sunday, August 03, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
James G. Evans

James G. Evans

About James G. Evans

Founder of PhenoVista, an in vitro biology CRO helping biopharma firms accelerate discovery screening. Scientific background in systems cell biology, imaging and informatics.

Research topics have included mechanisms of bacterial antibiotic resistance, gonadotrophin secretion pathways, immuno-oncology, macrophage adhesion and motility, neurodegeneration, mitochondrial diseases, adult and embryonic stem cell structure.

Related Story

Drug Development

FUJIFILM Cellular Dynamics and PhenoVista Biosciences Announce Strategic Alliance to Improve the Drug Discovery Process

January 7 2022

FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem […]